Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes

References

• Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2–9. doi:10.1634/theoncologist.13-S4-2.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of anti-tumor immunity by CTLA-4 blockade. Science. 1996;271:1734–1736. doi:10.1126/science.271.5256.1734.
   PubMed Web of Science ®Google Scholar
• Geng Q, Jiao P, Jin P, Su G, Dong J, Yan B. PD-1/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules. Curr Pharm Des. 2017;23:6033–6041. doi:10.2174/1381612823666171004120152.
   Web of Science ®Google Scholar
• Company B-MS. Yervoy (Ipilimumab) Prescribing Information. Princeton, NJ.: Bristol-Myers Squibb Company; 2020.
   Google Scholar
• Inc. MC. Keytrude (Pembrolizumab) Prescribing Information. Whitehouse Station, NJ: Merck & Co, Inc; 2020.
   Google Scholar
• Company B-MS. Opdivo (Nivolumab) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2020.
   Google Scholar
• Regeneron. Libtayo (Cemiplimab) Prescribing Information. Tarrytown, NY: Regeneron Pharmaceuticals Inc.; 2020.
   Google Scholar
• Inc G. Tecentriq (Atezolizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2020.
   Google Scholar
• Inc ES. Bavencio (Avelumab) Prescribing Information. Rockland: EMD Serono Inc.; 2020.
   Google Scholar
• LP. AP. Imfinzi (Durvalumab) Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020.
   Google Scholar
• Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–681. doi:10.1016/S1470-2045(18)30139-6.
   PubMed Web of Science ®Google Scholar
• Dalvin L, Shields C, Orloff M, et al. Checkpoint inhibitor immunotherapy: systemic indications and ophthalmic side effects. Retina. 2018;38:1063–1078. doi:10.1097/IAE.0000000000002181.
   PubMed Web of Science ®Google Scholar
• Kini A, Fu R, Compton C. et al. Pembrolizumab for recurrent conjunctival melanoma. JAMA Ophthalmol. 2017;135:891–892. doi:10.1001/jamaophthalmol.2017.2279.
   PubMed Web of Science ®Google Scholar
• Ford J, Thuro BA, Thakar S. et al. Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa. Ophthal Plast Reconstr Surg. 2017;33:e82–5.
   PubMed Web of Science ®Google Scholar
• Heppt MV, Steeb T, Schlager JG, et al. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review. Cancer Treat Rev. 2017;60:44–52. doi:10.1016/j.ctrv.2017.08.009.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. NEJM. 2018;378:158–168. doi:10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–1353. doi:10.1001/jamaoncol.2016.1051.
   PubMed Web of Science ®Google Scholar
• Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8(1):e53745. doi:10.1371/journal.pone.0053745.
   PubMed Web of Science ®Google Scholar
• Sun Mm MD,PD, Levinson RMD, Filipowicz ADO, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2019:28(2):1–11.
   Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. SUNWorkingGroup. Standardization of Uveitis Nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Institute NC Surveillance, Epidemiology and End Results program. SEER stat fact sheets: melanoma of the skin. 2020; Available from: https://seer.cancer.gov/statfacts/html/melan.html.
   Google Scholar
• Manusow J, Khoja L, Pesin N, et al. Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother can. 2014;2(41):1–4. doi:10.1186/s40425-014-0041-1.
   PubMedGoogle Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. doi:10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95. doi:10.1186/s40425-017-0300-z.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255–289. doi:10.6004/jnccn.2019.0013.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events v5.0. 2004 January 6, 2020; Available from: https://safetyprofiler-ctep.nci.nih.gov/CTC/CTC.aspx.
   Google Scholar
• Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–3814. doi:10.1200/JCO.2017.73.2289.
   PubMed Web of Science ®Google Scholar